ChanTest Acquires Applied Cell Sciences
News Feb 27, 2009
ChanTest, a provider of ion channel testing services and validated cell lines, announced that it has acquired Rockville, Maryland-based Applied Cell Sciences. ACS is a contract research organization (CRO) specializing in GPCRs.
The combined company will maintain both facilities in Rockville and Cleveland. Jesse Baumgold, Ph.D., who has led ACS since its inception in 2004, has been named ChanTest vice president of business development and product strategy. He will continue to direct the company's operations in Rockville. Terms of the acquisition were not disclosed.
Applied Cell Sciences products and services include optimized GPCR functional analysis tools, high-throughput screening reagents and reagent-development services, stable GPCR cell lines, cell membranes for binding studies, cryopreserved growth-arrested cells, custom cell line construction, gene-to-screen cell line construction and validation, large-scale cell cryopreservation, and specialized screening services. Going forward, ACS products and services will be marketed under the ChanTest name.
ChanTest's acquisition of ACS has been executed to ensure continuity of management, quality science, and service to clients. Customers are encouraged to contact their existing ChanTest or ACS representative to learn about the combined company's expanded portfolio of cell-based assays and reagents, new division-arrested cell lines, membrane preparations, and large cell line scale-up capabilities.
New Inherited Neurodevelopmental Disease DiscoveredNews
Researchers have identified a new inherited neurodevelopmental disease that causes slow growth, seizures and learning difficulties in humans.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE